Targets › GNAO1
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Dec 2026.
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades, such as regulation of postsynaptic neurotransmitter release. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. (UniProt, P09471)
Open in Phaseline: the race on GNAO1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pirogov Russian National Research Medical University | ASO-GNAO1 (Tianasen) Antisense oligonucleotide targeting GNAO1 | GNAO1 | Phase 1 | GNAO1 | Dec 2026 |
GNAO1 (1)
other (1)
Pirogov Russian National Research Medical University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.